Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
31 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
S.L.A. Pharma AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'S.L.A. Pharma AG - Product Pipeline Review - 2014', provides an overview of the S.L.A. Pharma AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of S.L.A. Pharma AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of S.L.A. Pharma AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of S.L.A. Pharma AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the S.L.A. Pharma AG's pipeline products Reasons to buy - Evaluate S.L.A. Pharma AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of S.L.A. Pharma AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the S.L.A. Pharma AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of S.L.A. Pharma AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of S.L.A. Pharma AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of S.L.A. Pharma AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 S.L.A. Pharma AG Snapshot 5 S.L.A. Pharma AG Overview 5 Key Information 5 Key Facts 5 S.L.A. Pharma AG - Research and Development Overview 6 Key Therapeutic Areas 6 S.L.A. Pharma AG - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 S.L.A. Pharma AG - Pipeline Products Glance 10 S.L.A. Pharma AG - Late Stage Pipeline Products 10 Phase III Products/Combination Treatment Modalities 10 S.L.A. Pharma AG - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 S.L.A. Pharma AG - Drug Profiles 12 diltiazem hydrochloride 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 icosapent ethyl 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 metronidazole 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 naloxone hydrochloride SR 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 phenylephrine 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 S.L.A. Pharma AG - Pipeline Analysis 20 S.L.A. Pharma AG - Pipeline Products by Target 20 S.L.A. Pharma AG - Pipeline Products by Route of Administration 21 S.L.A. Pharma AG - Pipeline Products by Molecule Type 22 S.L.A. Pharma AG - Pipeline Products by Mechanism of Action 23 S.L.A. Pharma AG - Recent Pipeline Updates 24 S.L.A. Pharma AG - Dormant Projects 27 S.L.A. Pharma AG - Discontinued Pipeline Products 28 Discontinued Pipeline Product Profiles 28 diltiazem hydrochloride 28 S.L.A. Pharma AG - Locations And Subsidiaries 29 Head Office 29 Other Locations & Subsidiaries 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 31 Disclaimer 31
List of Tables S.L.A. Pharma AG, Key Information 5 S.L.A. Pharma AG, Key Facts 5 S.L.A. Pharma AG - Pipeline by Indication, 2014 7 S.L.A. Pharma AG - Pipeline by Stage of Development, 2014 8 S.L.A. Pharma AG - Monotherapy Products in Pipeline, 2014 9 S.L.A. Pharma AG - Phase III, 2014 10 S.L.A. Pharma AG - Phase II, 2014 11 S.L.A. Pharma AG - Pipeline by Target, 2014 20 S.L.A. Pharma AG - Pipeline by Route of Administration, 2014 21 S.L.A. Pharma AG - Pipeline by Molecule Type, 2014 22 S.L.A. Pharma AG - Pipeline Products by Mechanism of Action, 2014 23 S.L.A. Pharma AG - Recent Pipeline Updates, 2014 24 S.L.A. Pharma AG - Dormant Developmental Projects,2014 27 S.L.A. Pharma AG - Discontinued Pipeline Products, 2014 28 S.L.A. Pharma AG, Subsidiaries 29
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.